EH
PLX icon

Equitable Holdings’s Protalix BioTherapeutics PLX Stock Holding History

Equitable Holdings’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$30.6K Buy
13,150
+2,000
+18% +$4.24K ﹤0.01% 1790
2026
Q1 		$20.1K Hold
11,150
– – ﹤0.01% 1678
2025
Q4 		$20.1K Buy
+11,150
New +$22.8K ﹤0.01% 1570

Other funds holding PLX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SWP
Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Equitable Holdings's PLX Position: Q2 2026 in Review

Equitable Holdings increased its Protalix BioTherapeutics (PLX) stake by 18% in Q2 2026, buying an estimated $4.24K and bringing the position to 13,150 shares worth $30.6K. The position accounts for ﹤0.01% of the portfolio, ranked #1790.

Equitable Holdings first reported a position in PLX in Q4 2025 and has held it in 3 quarters since. 102 funds tracked by Wall St. Rank hold PLX as of Q2 2026.

  • Equitable Holdings held 13,150 shares of Protalix BioTherapeutics worth $30.6K as of Q2 2026.
  • Equitable Holdings bought 2,000 Protalix BioTherapeutics shares in Q2 2026, an estimated $4.24K.
  • Protalix BioTherapeutics made up ﹤0.01% of Equitable Holdings's portfolio in Q2 2026, its #1790 holding.
  • Equitable Holdings first reported a position in Protalix BioTherapeutics in Q4 2025 and has held it in 3 quarters since.
  • 102 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2026.

Based on Equitable Holdings's 13F filing for Q2 2026, filed 17 Aug 2026.